You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

An Update on C3 Glomerulopathy: Understanding a Rare Complement-Mediated Kidney Disease

  • Authors: Carla M. Nester, MD, MSA, FASN; Christoph Licht, MD, FRCP(C), FASN; Manuel Praga, MD, PhD
  • CPD Released: 8/31/2022
  • Valid for credit through: 8/31/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.50 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US primary care providers, nephrologists, and allergists/clinical immunologists.

The goals of this activity are that learners will be better able to diagnose and select an appropriate treatment for C3G.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Pathophysiology of C3G
    • Recommended diagnostic tests for the differential diagnosis of C3G
    • Current and emerging therapies for C3G


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Faculty

  • Carla M. Nester, MD, MSA, FASN

    Jean E. Robillard, MD, Chair in Pediatric Nephrology
    Director, Division of Pediatric Nephrology, Dialysis and Transplantation
    Associate Director, Molecular Otolaryngology and Renal Research Laboratory
    Iowa City, Iowa
    United States

    Disclosures

    Carla M. Nester, MD, MSA, FASN, has the following relevant financial relationships:
    Consultant or advisor for: Achillion; Alexion; Apellis; Biocryst; Chemocentryx; Novartis
    Research funding from: Clinical Trials: Achillion; Apellis; Biocryst; Chemocentryx; Novartis

  • Christoph Licht, MD, FRCP(C), FASN

    Cell Biology Program, SickKids Research Institute
    Department of Pediatrics, Faculty of Medicine, University of Toronto
    Division of Nephrology, The Hospital for Sick Children
    Toronto, Ontario, Canada

     

    Disclosures

    Christoph Licht, MD, FRCP(C), FASN, has the following relevant financial relationships:
    Consultant or advisor for: Alexion; AstraZeneca Rare Disease Pharmaceuticals, Inc; Apellis Pharmaceuticals, Inc; Catalyst Biosciences; Elva GmbH; Novartis
    Speaker or member of speakers bureau for: Alexion; AstraZeneca Rare Disease Pharmaceuticals, Inc; Elva GmbH
    Research funding from: Aurin Biotech; Fresenius; Pfizer Inc.

  • Manuel Praga, MD, PhD

    Instituto de Investigación Hospital 12 de octubre (imas12)
    Department of Medicine, Universidad Complutense de Madrid
    Department of Nephrology
    Hospital Universitario 12 de Octubre
    Madrid, Spain

     

    Disclosures

    Manuel Praga, MD, PhD, has the following relevant financial relationships:
    Consultant or advisor for: Alexion; Apellis, Aurinia; GlaxoSmithKline; Novartis; Otsuka; Roche; Silence; Travere
    Speaker or member of speakers bureau for: Alexion; Apellis; Aurinia; GlaxoSmithKline; Novartis; Otsuka; Roche; Silence; Travere

Editors

  • Rita Moreira Da Silva, PhD, PharmD

    Medical Education Director, WebMD Global, LLC

     

    Disclosures

    Rita Moreira Da Silva, PhD, PharmD, has no relevant financial relationships.

  • Grace O’Malley, PhD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Grace O’Malley, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Susan L. Smith, MN, PhD

    Associate Director, Accreditation and Compliance

    Disclosures

    Susan L. Smith, MN, PhD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

An Update on C3 Glomerulopathy: Understanding a Rare Complement-Mediated Kidney Disease

Authors: Carla M. Nester, MD, MSA, FASN; Christoph Licht, MD, FRCP(C), FASN; Manuel Praga, MD, PhDFaculty and Disclosures

CPD Released: 8/31/2022

Valid for credit through: 8/31/2023

processing....

Contents of This CPD Activity

All sections of this activity are required for credit.

An Update on C3 Glomerulopathy: Understanding a Rare Complement-Mediated Kidney Disease

Did you know that up to 70% of children and 30% to 50% of adults, respectively, with C3G reach kidney failure within 10 years?
Carla M. Nester, MD, MSA, FASN

Clinical Presentation of C3 Glomerulopathy

C3G is an umbrella term for several rare kidney diseases highly variable in nature, with overlapping clinical and pathologic manifestations.
Christoph Licht, MD, FRCP(C), FASN

Histologic Patterns and Testing for C3 Glomerulopathy

How familiar are you with the reclassification of membranoproliferative glomerulonephritis (MPGN) and how to distinguish immunocomplex-mediated MPGN from complement-mediated MPGN?
Christoph Licht, MD, FRCP(C), FASN

Treatment and Prognosis: Why Is It So Important to Treat Early?

Did you know that it is generally accepted that 50% of patients with C3G will experience a recurrence?
Carla M. Nester, MD, MSA, FASN

Current and Emerging Therapies

Standard treatment for C3G is expert opinion based. Learn how emerging agents can contribute to outcomes in patients with C3G.
Manuel Praga, MD
 

Educational Impact Challenge

The goals of this activity are that learners will be better able to diagnose and select an appropriate treatment for C3G.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.